# West Pharmaceutical Services, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/West Pharmaceutical Services, Inc).

## Overview

West Pharmaceutical Services is a U.S.-based manufacturer of containment and delivery systems used with injectable drugs and healthcare products. Its business spans proprietary packaging and drug-delivery components, contract manufacturing, analytical lab services, and integrated solutions for pharmaceutical, biologic, diagnostic, and medical device customers worldwide.

## Products & services

• Primary packaging and containment systems
• Reconstitution and transfer systems
• Drug delivery components and devices
• Contract manufacturing and automated assembly
• Analytical lab services and integrated solutions

- **Proprietary Products** (65%) — Proprietary packaging, containment, and drug-delivery components for injectable therapies.
- **Contract-Manufactured Products** (35%) — Design, manufacture, and automated assembly of complex devices and components for customers.

- Primary packaging and containment systems
- Reconstitution and transfer systems
- Drug delivery components and devices
- Contract manufacturing and automated assembly
- Analytical lab services and integrated solutions

## Customers

West sells to pharmaceutical, biologic, generic, diagnostic, and medical device companies that need components or outsourced manufacturing for injectable and device-based products. Customers buy West’s systems to support product compatibility, regulatory compliance, sterile handling, and efficient delivery to patients. A small number of large customers account for a meaningful share of revenue, making customer concentration an important feature of the business.

- **Biologic pharmaceutical companies** (primary) — Buy containment and delivery systems for injectable biologics and specialty therapies; they value quality, compatibility, and regulatory support.
- **Generic and traditional pharmaceutical companies** (primary) — Buy packaging components, transfer systems, and delivery devices for injectable medicines and line integration.
- **Diagnostic and medical device companies** (secondary) — Buy contract-manufactured components and assembled devices for further processing or end-use products.
- **Large strategic accounts** (primary) — High-volume customers that purchase across both proprietary and contract-manufacturing segments.

- Biologic drug makers using injectable containment and delivery systems
- Generic and pharmaceutical companies buying primary packaging components
- Diagnostic and medical device firms outsourcing device assembly
- Customers seeking regulatory support, compatibility studies, and technical service
- Large accounts that can represent a significant share of sales

## Geography

West operates as a global business with manufacturing, sales, and support activities across the United States and many international markets. The company also maintains collaborations in Japan and Mexico, and it holds a substantial portion of cash outside the U.S., reflecting its international operating footprint. Geography matters because customer demand, tariffs, currency movements, and local regulatory requirements can affect sourcing, production, and sales execution.

- Global manufacturing and sales footprint across major pharmaceutical markets
- U.S. base with significant operations and cash held outside the U.S.
- Collaborations in Japan and Mexico support technology sharing and market access
- International exposure creates tariff, customs, and currency risk
- Local manufacturing capability helps serve multinational customers

## Strategy

West’s strategy centers on being a full-service supplier of high-quality injectable drug containment and delivery systems, supported by engineering, analytical, and regulatory expertise. It also emphasizes global manufacturing flexibility, multi-site production, and automated assembly capabilities to serve large pharmaceutical customers and complex programs. The company’s position depends on innovation in drug-delivery technologies and on maintaining trusted relationships with customers that value reliability and technical support.

- **Broaden integrated drug-delivery solutions** (medium-term) — Customers want suppliers that can combine packaging, device, and technical support in one platform.
- **Strengthen global manufacturing flexibility** (medium-term) — Multinational customers value supply continuity and local production options.
- **Advance proprietary delivery technologies** (long-term) — Innovation helps defend against commoditization and alternative delivery formats.
- **Improve automated assembly capabilities** (short-term) — Automation supports complex device production and competitive cost structure.

- Expand integrated containment and delivery offerings for injectable drugs
- Use global manufacturing to support multi-site customer programs
- Differentiate through engineering, regulatory, and analytical support
- Invest in automated assembly and advanced manufacturing technologies
- Develop products for alternative delivery methods and new therapies

## Risks

West faces customer concentration, pricing pressure, and intense competition across both proprietary components and contract manufacturing. Its results also depend on continued demand for injectable therapies, while international operations expose it to tariffs, supply disruptions, currency effects, and local regulatory complexity. Accounting and valuation risk is meaningful because goodwill, long-lived assets, and inventory levels depend on assumptions about future demand and cash flows.

- **Customer concentration** [high] — Ten customers represented a large share of consolidated sales, so account loss or volume shifts can materially affect revenue.
- **Pricing pressure** [high] — Large pharmaceutical customers and competitors can force lower prices or tougher contract terms.
- **Shift away from injectable therapies** [high] — The business depends on products delivered by injection; alternative delivery methods could reduce demand.
- **International trade and regulatory exposure** [medium] — Operations span multiple countries, creating exposure to tariffs, customs controls, and local compliance requirements.
- **Impairment risk on goodwill and long-lived assets** [medium] — Valuations depend on future cash flows, product demand, and innovation success.

- Customer concentration can amplify the impact of a lost or delayed program
- Pricing pressure from large pharma buyers can compress margins
- Demand could weaken if therapies shift away from injection delivery
- International operations face tariffs, customs, and regulatory risk
- Goodwill and asset values depend on future sales and cash-flow assumptions

## Accounting

West’s reported results are sensitive to revenue mix, customer concentration, and the timing of shipments and services across product lines and geographies. Investors should also watch impairment testing for goodwill and long-lived assets, because those estimates depend on future sales, cash flows, and discount rates tied to injectable-drug demand. Inventory, purchase commitments, leases, and hedging liabilities can also move working capital and reported earnings as the company manages a global manufacturing network.

- **Revenue recognition and shipment timing** — Quarterly comparability
- **Goodwill impairment** — Could create material non-cash charges
- **Long-lived asset impairment** — May affect operating results and asset values
- **Inventory and purchase commitments** — Working capital and supply-chain exposure
- **Derivatives and foreign currency** — Earnings and balance-sheet volatility

- Revenue mix and shipment timing affect quarterly comparability
- Goodwill impairment depends on future sales and cash-flow assumptions
- Long-lived asset impairment can be triggered by demand changes
- Purchase commitments and inventories reflect supply planning
- Foreign-currency and hedge liabilities can affect working capital

---

*Last updated: 2026-08-11T04:03:56.228997+00:00*